Last reviewed · How we verify
serum physiologic
Serum physiologic is a sterile saline solution that replaces or supplements body fluids and electrolytes to maintain physiological balance.
Serum physiologic is a sterile saline solution that replaces or supplements body fluids and electrolytes to maintain physiological balance. Used for Dehydration and fluid replacement, Electrolyte imbalance correction, Perioperative fluid management.
At a glance
| Generic name | serum physiologic |
|---|---|
| Also known as | izotonic fluid, Group III |
| Sponsor | TC Erciyes University |
| Drug class | Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / Fluid Management |
| Phase | FDA-approved |
Mechanism of action
This is a basic intravenous or topical fluid replacement therapy containing sodium chloride and other electrolytes in concentrations matching normal blood serum. It is used to restore fluid volume, correct electrolyte imbalances, and maintain osmotic pressure in patients with dehydration, blood loss, or electrolyte disturbances.
Approved indications
- Dehydration and fluid replacement
- Electrolyte imbalance correction
- Perioperative fluid management
- Wound irrigation and topical use
Common side effects
- Hypernatremia (with excessive use)
- Fluid overload / pulmonary edema
- Hypokalemia (if potassium not supplemented)
- Phlebitis (at IV site)
Key clinical trials
- Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Whey Protein Supplementation and Serum Mineral Status in Elite Endurance and Power Athletes (NA)
- Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Combination of Oral and Topical Whitening Agents for Reducing Skin Pigmentation (NA)
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- serum physiologic CI brief — competitive landscape report
- serum physiologic updates RSS · CI watch RSS
- TC Erciyes University portfolio CI